TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02988960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous
Study: NCT03228186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: 25mg/m2 days 1, 3, 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 day 1
Study: NCT01634243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT05760625

Intervention type: DIAGNOSTIC_TEST
Intervention: analysis BDNF
Description: We analysed consentration of BDNF in venous blood of patient with primary headache

Intervention type: DIAGNOSTIC_TEST
Intervention: analysis BDNF
Description: We analysed consentration of BDNF in venous blood of patient with primary headache

Intervention type: DIAGNOSTIC_TEST
Intervention: analysis BDNF
Description: We analysed consentration of BDNF in venous blood of patient with primary headache
Study: NCT03162718

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
Study: NCT01548664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Fit
Description: 15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Extremity Exercise
Description: Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
Study: NCT02688075

Intervention type: OTHER
Intervention: No Intervention
Description: Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
Study: NCT02998502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freespira Breathing System
Description: Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
Study: NCT02375776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CORA- Device:smartphones
Description: Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
Study: NCT04454814

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protaper Universal instruments
Description: Root canal treatment using Protaper Universal instruments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reciproc Blue instruments
Description: Root canal treatment using Reciproc Blue instruments
Study: NCT03069183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Ropivacaine
Description: Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
Study: NCT01523444

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: computer-assisted Screening & Brief Advice
Description: The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and talking points designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-assisted Screening & Brief Advice Plus
Description: The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
Study: NCT01713127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00490997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine only
Description: Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine - Propofol
Description: Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation
Study: NCT04942509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coloring as a brief mindfulness-based intervention
Description: Participants watched an instructional video on mindful coloring at the beginning of the intervention and colored mindfully for at least 5 days or 100 minutes in total during a 10-day period. The intervention included a coloring booklet that contained mandala patterns for coloring.
Study: NCT04453254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Food Meal
Description: Isocaloric/ macronutrient whole food meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplement Food Meal
Description: Isocaloric/ macronutrient supplement food meal
Study: NCT02421965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS (Smartphone Application)
Description: Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WRAP (Wellness Recovery Action Planning)
Description: Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
Study: NCT03889262

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hippotherapy
Description: Hippotherapy is a therapeutic method in which a mechanical horse is used for therapeutic purposes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy
Description: Neurodevelopmental therapy (NDT) is a hands-on treatment approach used by physical therapists, occupational therapists, and speech-language pathologists. NDT was developed to enhance the function of children who have difficulty controlling movement as a result of neurological challenges, such as cerebral palsy and head injury. During treatment interventions, repeated experience in movement ensures that a particular pattern is readily accessible for motor performance. The more a patient performs certain movements, the easier these movements becomes.
Study: NCT04924725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided fine needle biopsy
Description: Endoscopic ultrasound-guided fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided fine needle biopsy
Description: Endoscopic ultrasound-guided fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions
Study: NCT03889262

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy
Description: Neurodevelopmental therapy (NDT) is a hands-on treatment approach used by physical therapists, occupational therapists, and speech-language pathologists. NDT was developed to enhance the function of children who have difficulty controlling movement as a result of neurological challenges, such as cerebral palsy and head injury. During treatment interventions, repeated experience in movement ensures that a particular pattern is readily accessible for motor performance. The more a patient performs certain movements, the easier these movements becomes.
Study: NCT03485456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Description: Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
Study: NCT03950388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Wards randomly assigned to receive the intervention will have a Band 8a Psychologist based on the ward for 0.5FTE for 7 months. During this time, all patients will be involved with the proposed stepped model of care intervention at one of three levels. The level the patient receives will be decided by the multidisciplinary ward team. At Step one, all patients will have a psychological formulation developed by the psychologist in conjunction with the patient or members of the ward team. At Step 2, all qualified nurses will be trained and supervised to deliver guided self-help material of psychological interventions targeting key problem areas for patients. At Step 3, patients will be offered up to 16, one-to-one therapy sessions with the psychologist.
Study: NCT03757676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Play
Description: Participants in this group were asked not to download or play Pokémon Go during the study period and were asked to simply continue with their normal daily activities. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: At Will Play
Description: Participants in this group were asked to download Pokémon Go and play for at least 30 minutes initially, then play as much or as little as desired during the 4 week intervention period, with no specific instruction or goals for play. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Oriented Play
Description: Participants in this group were asked to download and play Pokémon Go and achieve a minimum player level of 20 within the game during the study period. They were given materials that described game features and functions to show them how to play the game. There were no restrictions on which features to pursue within the game to achieve this goal nor on how long or how frequent their play sessions should be. Upon reaching their goal (Level 20), participants were encouraged to continue to play as much or as little as they desired. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
Study: NCT00812097

Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Siltex® Contour Profile Gel Mammary Prosthesis
Description: The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
Study: NCT03744234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: Autologous platelet-rich plasma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Injection
Description: Steroid injection
Study: NCT02039388

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
Study: NCT02035943

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Insulin separated
Description: separate continuos infusion of insulin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Insulin added to parenteral nutrition
Description: Insulin added to parenteral nutrition
Study: NCT00652587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatectomy and transcatheter arterial chemoembolization
Description: partial hepatectomy with adjuvant transcatheter arterial chemoembolization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatectomy
Description: hepatectomy alone
Study: NCT00812097

Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Siltex® Contour Profile Gel Mammary Prosthesis
Description: The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.

Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Siltex® Contour Profile Gel Mammary Prosthesis
Description: The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.

Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Siltex® Contour Profile Gel Mammary Prosthesis
Description: The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
Study: NCT01585649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim
Description: Lipegfilgrastim 100ug/kg
Study: NCT02299934

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI sequences for visualisation of the blood supply of liver without contrast agent.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Compurtized Tomgraphy (CT)
Description: CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
Study: NCT04036760

Intervention type: BEHAVIORAL
Intervention: Research transitional care coordination
Description: Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
Study: NCT00716521

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single oral dose placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: single oral dose, 5 mg zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: single oral dose, 10 mg zolpidem
Study: NCT03590561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High caloric diet
Description: After dietary counseling, subjects will receive high caloric snacks for five days.
Study: NCT00989326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Monitoring
Description: Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
Study: NCT02984475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT03778333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: IV therapy with autologous bone-marrow derived mesenchymal stem cells
Study: NCT01655407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Engineered Skin Substitute
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Engineered Skin Substitute
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split-Thickness Autograft (AG)
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split-Thickness Autograft (AG)
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin.
Study: NCT04353947

Intervention type: DIAGNOSTIC_TEST
Intervention: Mini Cognitive Examination (MCE)
Description: This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Mini Cognitive Examination (MCE)
Description: This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Mini Cognitive Examination (MCE)
Description: This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Depression Inventory-II (BDI-II)
Description: This test evaluates the absence or presence of depressive symptoms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Depression Inventory-II (BDI-II)
Description: This test evaluates the absence or presence of depressive symptoms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Depression Inventory-II (BDI-II)
Description: This test evaluates the absence or presence of depressive symptoms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Global Deterioration Scale (GDS)
Description: This scale measures the level of deterioration of the subject.
Study: NCT03341429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Saxenda]
Description: Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous injection
Study: NCT04353947

Intervention type: DIAGNOSTIC_TEST
Intervention: Global Deterioration Scale (GDS)
Description: This scale measures the level of deterioration of the subject.
Study: NCT01773902

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Protein (Individualized)
Description: Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if \<1500g b.w. or 4.0g/kg/d of enteral protein if \>1500g b.w. until 1 week before discharge

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Protein (Standardized)
Description: Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Protein Supplementation
Description: Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
Study: NCT03228576

Intervention type: COMBINATION_PRODUCT
Intervention: Extended release Tacrolimus-Everolimus association
Description: Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus